In Silico Children and the Glass Mouse Model: Clinical Trial Simulations To Identify and Individualize Optimal Isoniazid Doses in Children with Tuberculosis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2010-11-22

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1128/AAC.00763-10PMID 21098246PMCID PMC3028779
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic Drug Monitoring in the Treatment of Tuberculosis

  2012cited by this paper
• Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB.

  2010cited by this paper
• Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used

  2010cited by this paper
• Practical, Individualized Dosing: 21st Century Therapeutics and the Clinical Pharmacometrician

  2010cited by this paper
• An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future

  2010cited by this paper
• New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

  2010cited by this paper
• Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

  2009cited by this paper
• Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

  2009cited by this paper
• Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs

  2009cited by this paper
• The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy

  2009cited by this paper
• A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.

  2009cited by this paper
• Paediatric tuberculosis.

  2008cited by this paper
• Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro.

  2008cited by this paper
• Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro

  2008influential reference
• Low-dose inhaled versus standard dose oral form of anti-tubercular drugs: concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum.

  2008cited by this paper
• Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy.

  2008cited by this paper
• NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.

  2007cited by this paper
• Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

  2007cited by this paper
• Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid

  2007cited by this paper
• Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia

  2007cited by this paper
• Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations

  2007influential reference
• Guidance for National Tuberculosis Programmes on the management of tuberculosis in children - an update.

  2007cited by this paper
• Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 1: introduction and diagnosis of tuberculosis in children.

  2006cited by this paper
• Guidance for National Tuberculosis Programmes on the management of tuberculosis in children CHAPTER 1 IN THE SERIES

  2006cited by this paper
• The Monte-Carlo Method

  2006influential reference
• Tuberculous meningitis and miliary tuberculosis: the Rich focus revisited.

  2005cited by this paper
• Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?

  2005cited by this paper
• Isoniazid pharmacokinetics in children treated for respiratory tuberculosis

  2005cited by this paper
• Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia

  2005cited by this paper
• Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.

  2004cited by this paper
• Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.

  2004cited by this paper
• Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

  2004cited by this paper
• Isoniazid Pharmacokinetics-Pharmacodynamics in an Aerosol Infection Model of Tuberculosis

  2004cited by this paper
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

  2003cited by this paper
• Paediatric tuberculosis

  2003cited by this paper
• Effects of Gender, AIDS, and Acetylator Status on Intrapulmonary Concentrations of Isoniazid

  2002influential reference
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis

  2002cited by this paper
• Dosages of anti-tuberculosis medications in the national tuberculosis programs of Kenya, Nepal, and Senegal.

  2002cited by this paper
• Isoniazid pharmacokinetics in children according to acetylator phenotype

  2001influential reference
• Extra-pulmonary tuberculosis in children

  2000cited by this paper
• Role of Acid pH and Deficient Efflux of Pyrazinoic Acid in Unique Susceptibility of Mycobacterium tuberculosis to Pyrazinamide

  1999influential reference
• [Multicenter evaluation of broth microdilution test, BrothMIC MTB, to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for Mycobacterium tuberculosis--evaluation of interlaboratory precision and interpretive compatibility with agar proportion method].

  1999influential reference
• Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

  1997influential reference
• Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis.

  1997influential reference
• In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.

  1996influential reference
• Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

  1993cited by this paper
• Drug susceptibility in the chemotherapy of mycobacterial infections

  1992cited by this paper
• Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status.

  1992cited by this paper
• Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation.

  1990cited by this paper
• Kinetics of isoniazid transfer into cerebrospinal fluid in patients with tuberculous meningitis.

  1990cited by this paper
• Uptake of antibiotics by human alveolar macrophages.

  1984cited by this paper
• Uptake of antibiotics by human alveolar macrophages.

  1984influential reference
• Antibiotic entry into human polymorphonuclear leukocytes

  1982influential reference
• Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

  1954influential reference
• The Monte Carlo method.

  1949cited by this paper

• Exploring the Power and Promise of In Silico Clinical Trials with Application in COVID-19 Infection

  2021cites this paper
• Computing Personalised Treatments through In Silico Clinical Trials. A Case Study on Downregulation in Assisted Reproduction

  2020cites this paper
• Optimal Personalised Treatment Computation through In Silico Clinical Trials on Patient Digital Twins

  2020cites this paper
• Pharmacokinetics of First-Line Anti-Tubercular Drugs

  2019cites this paper
• Computing Personalised Treatments through In Silico Clinical Trials

  2018cites this paper
• A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting

  2017cites this paper
• Systems Immunology Approaches for Precision Medicine

  2017cites this paper
• pathogen-microbiota interactions during Clostridium difficile infection and the use of this model for the development of the hypothesis that host-antimicrobial peptide production may correlate with increased disease severity and promote increased recurrence. Secondly, it provides insight into the ne

  2017cites this paper
• The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

  2017cites this paper
• Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection

  2017cites this paper
• Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks

  2016cites this paper
• The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism

  2016cites this paper
• A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground

  2016cites this paper
• Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests

  2016cites this paper
• UNIVERSITÁ DEGLI STUDI DI UDINE

  2015cites this paper
• A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

  2015cites this paper
• Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.

  2015cites this paper
• Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.

  2015cites this paper
• Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.

  2015cites this paper
• A multi-scale approach to designing therapeutics for tuberculosis.

  2015cites this paper
• Pharmacokinetic/pharmacodynamic relationship and simulation analysis for the evaluation of isoniazid hepatotoxicity risk development in patients with tuberculosis

  2015cites this paper
• In reply: Acquired drug-resistance because of pharmacokinetic variability in a young child with tuberculosis.

  2014cites this paper
• Chapter 36 – Tuberculosis

  2014cites this paper
• Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosis.

  2014cites this paper
• Design of a drug‐drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation

  2014cites this paper
• Therapy duration and long-term outcomes in extra-pulmonary tuberculosis

  2014cites this paper
• Hollow Fiber System Model of Tuberculosis (HFS-TB) as an in vitro preclinical tool for optimization of dose selection and drug regimen in anti-TB drug development

  2014cites this paper
• Pharmacogenomics and Personalized Medicine for Infectious Diseases

  2013cites this paper
• Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.

  2013cites this paper
• Role of pharmacogenomics in the treatment of tuberculosis: a review

  2012cites this paper
• Simultaneous Determination of Isoniazid and Acetylisoniazid in Human Plasma by Hydrophilic Interaction Liquid Chromatography Tandem Mass Spectrometry and Its Application to a Pharmacokinetics Related to N-Acetyltransferase2 Genetic Polymorphism

  2012cites this paper
• In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens.

  2011cites this paper
• Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions

  2011cites this paper
• Population pharmacokinetics and its role in anti-tuberculosis drug development and optimization of treatment.

  2011cites this paper